EGFR and neoplasm: The ENSURE trial [52], published at the beginning of the previous decade, had proven the effectiveness of EGFR tyrosine kinase inhibitors (EGFR TKIs), namely erlotinib and gefitinib; in NSCLC patients with activating EGFR mutation detected in tumor tissue, that revolutionized the management of NSCLC treatment and has opened the era of personalized medicine in this field of oncology [53].